Perturbed activation of the LOX-1 pathway may explain the increased risk of cardiovascular events in SLE patients, and the inhibition of the LOX-1 pathway may provide protection from the development of cardiovascular disease. Here, OLR1 is linked to systemic lupus erythematosus.